title: Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676).
abstract: We report a patient with acute promyelocytic leukaemia (APL) who received two doses of gemtuzumab ozogamicin for advanced disease. Previous treatments included front-line all-trans retinoic acid and anthracyclines, polychemotherapy consolidation, salvage chemotherapy for the first relapse followed by autologous stem cell transplantation (ASCT), arsenic trioxide for the second relapse followed by a second ASCT and then high-dose methotrexate for more advanced systemic disease with central nervous system involvement. The patient achieved prolonged haematological and molecular remission after monotherapy with gemtuzumab ozogamicin given at the time of the third relapse.
authors.affiliation: Department of Cellular Biotechnology and Haematology, University La Sapienza, Roma, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Petti
authors.forename: M B
authors.initials: MB
authors.lastname: Pinazzi
authors.forename: D
authors.initials: D
authors.lastname: Diverio
authors.forename: A
authors.initials: A
authors.lastname: Romano
authors.forename: M T
authors.initials: MT
authors.lastname: Petrucci
authors.forename: S
authors.initials: S
authors.lastname: De Santis
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: A
authors.initials: A
authors.lastname: Tafuri
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
authors.forename: F
authors.initials: F
authors.lastname: Lo Coco
mesh_terms: D000328:Adult; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D002490:Central Nervous System / Q000276:immunology; D003131:Combined Modality Therapy; D005260:Female; D000079982:Gemtuzumab; D015321:Gene Rearrangement; D019450:Genes, MDR; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology; D017254:Leukemic Infiltration; D010087:Oxides / Q000627:therapeutic use; D063268:Sialic Acid Binding Ig-like Lectin 3; D014178:Translocation, Genetic; D014212:Tretinoin / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D001152:Arsenicals; C571163:CD33 protein, human; D010087:Oxides; D063268:Sialic Acid Binding Ig-like Lectin 3; D014212:Tretinoin; D000079982:Gemtuzumab; D000077237:Arsenic Trioxide